Targets › CA2
5 programs from 5 companies in 28 trials: 11 Phase 4, 8 Phase 2, 8 Phase 1, 1 Phase 3; Ophthalmology, Neurology, Metabolic and endocrine; next expected readout Dec 2026.
Catalyzes the reversible hydration of carbon dioxide. Can also hydrate cyanamide to urea. (UniProt, P00918)
Open in Phaseline: the race on CA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tecnoquimicas | Preservative-free dorzolamide-timolol-brimonidine combination Carbonic anhydrase inhibitor (dorzolamide), beta-adrenergic antagonist (timolol), and alph | CA2, ADRB1, ADRA2A | Phase 4 | Primary Open-Angle Glaucoma (POAG) | Jul 2027 |
| University of Colorado, Denver | Methazolamide Carbonic anhydrase VII inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor | CA7, CA1, CA2, CA4 | Phase 4 | Glaucoma, Open-Angle | – |
| Upsher-Smith Laboratories | Topiramate Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist | CA2, CA4, GRIA4, GRIA3, GRIA2 | Phase 4 | Migraine Disorders; Obesity; Ménière; Liver Cirrhoses … | – |
| Shionogi | Acetazolamide Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor | CA1, CA2, CA12, CA4 | Phase 2 | Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain … | Dec 2026 |
| Incannex Healthcare | IHL-42X Dronabinol (cannabinoid CB1/CB2 receptor agonist) combined with acetazolamide (carbonic an | CNR1, CNR2, CA2 | Phase 2 | Obstructive Sleep Apnea (OSA) | Apr 2027 |
Sleep Apnea (3) Obstructive Sleep Apnea (3) Glaucoma, Open-Angle (1) Primary Open-Angle Glaucoma (POAG) (1) Migraine Disorders (1) Obesity (1) Ménière (1) Liver Cirrhoses (1) Post Traumatic Stress Disorder (1) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1)
small molecule (4)
University of Colorado, Denver (1) Tecnoquimicas (1) Upsher-Smith Laboratories (1) Shionogi (1) Incannex Healthcare (1)
CA4 (3) CA1 (2) CA7 (1) ADRB1 (1) ADRA2A (1) GRIA4 (1) GRIA3 (1) GRIA2 (1) CA12 (1) CNR1 (1) CNR2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.